Project Grant R56AG100463
Award Date 9/4/26
Completion Date 8/31/28
Dollars Obligated $674K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Durham, NC 27707, USA
Similar Awards
- The National Institute on Aging awarded the University of Alabama at Birmingham $405,955 on June 1, 2026, under the Aging Research program (CFDA 93.866) to develop and validate two novel retinal biomarkers for early Alzheimer's disease detection: retinal mid-peripheral capillary free zones and putative retinal gliosis. The award supports quantification and validation of these biomarkers using optical coherence tomography angiography and spectral domain OCT imaging, with the goal of providing a...
- The National Institute on Aging awarded Virginia Polytechnic Institute & State University $762,861 on September 1, 2026, under the Aging Research program (CFDA 93.866) to conduct research on transcriptomic dynamics associated with TDP-43 propagation in limbic-predominant age-related TDP-43 encephalopathy neuropathological change (LATE-NC). The project will use quantitative neuropathology and high-resolution spatial transcriptomics to map the distribution of TDP-43, tau, and amyloid-beta...
- The National Institute on Aging awarded The Washington University $246,225 on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop an ultrasensitive, multiplexed plasmonic-fluor-linked immunosorbent assay (P-FLISA) for quantitative measurement of plasma phosphorylated tau 217 (P-TAU217), amyloid-beta 42 (AB42), and amyloid-beta 40 (AB40) as neurological biomarkers for early Alzheimer's disease detection. The project will deliver two specific research aims. Aim 1...
- The National Institute on Aging, under the Department of Health and Human Services, awarded Duke University $627,830 on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop a portable diagnostic system for Alzheimer's disease detection using circulating microRNA biomarkers. Duke's project, titled ADMIRE (Alzheimer's Detection via miRNA Evaluation), integrates two technologies: an amplification-free microRNA biosensing modality called the Inverse Molecular Sentinel and a...
- The National Institute on Aging awarded Duke University $444,125 under the Aging Research program (CFDA 93.866) on September 3, 2026, to investigate bidirectional relationships between plasma tau phosphorylation markers and postoperative delirium. The project examines how Alzheimer's disease pathology, reflected in blood-based biomarkers such as threonine-217 phosphorylated tau (PTAU217), may increase postoperative delirium risk and how postoperative delirium may alter longitudinal...
- The National Institute on Aging awarded the University of Utah $437,252 on January 1, 2026, under the Aging Research program (CFDA 93.866) to develop and validate a plasma biomarker for TDP-43 proteinopathy in Alzheimer's disease and frontotemporal lobar degeneration. The project investigates MAB No. 9, a monoclonal antibody identified through screening over 5,000 antibody candidates that recognizes novel TDP-43 pathology in both diseases. Researchers will examine how MAB No. 9-positive TDP-43...
- The National Institute on Aging awarded the University of North Carolina at Chapel Hill $210,513 on July 20, 2026, under the Aging Research program (CFDA 93.866) to characterize molecular products of TDP-43 dysfunction as neuroinflammatory targets in amyotrophic lateral sclerosis and frontotemporal dementia (ALS-FTD). The research investigates the interplay between TDP-43 dysfunction and antigen generation that drives maladaptive neuroinflammation in ALS-FTD. The work comprises two aims:...
- The National Institute on Aging awarded the Regents of the University of Michigan $126,969 on September 1, 2026, under the Aging Research program (CFDA 93.866) to conduct research determining the unique molecular and cellular features of limbic-predominant age-related TDP-43 encephalopathy (LATE). The recipient will compare the intrinsic properties of TDP-43 aggregates in FTLD-TDP (frontotemporal lobar degeneration with TDP-43 deposition) and LATE through high-resolution cryo-electron microscopy...
- The National Institute on Aging awarded the University of California, Berkeley $549,260 on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop advanced large language model-based AI tools that enhance precision in predicting Alzheimer's disease pathology and cognitive outcomes. The research addresses critical gaps in precision medicine for Alzheimer's disease, particularly the need to capture patient heterogeneity, accurately identify treatment candidates for...
- The National Institute on Aging awarded New York University $6.203 million on September 15, 2025, under the Aging Research program (CFDA 93.866) to examine peripheral immune markers and vascular dysfunction as contributors to cognitive decline and Alzheimer's disease. The research integrates circulating biomarkers—platelet aggregation, neutrophil activity, and proteomic data—with advanced imaging to assess associations between vascular and immune dysfunction and cerebrovascular burden, amyloid...